Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has expanded its pharmaceutical contract manufacturing agreement with Merck Sharp & Dohme (MSD), increasing the total contract value by KRW 154.6B from KRW 92.8B to KRW 247.3B following the commercialization success of the client’s product.
📊 [Key Disclosure Details & Financial Figures]
- Reason for Correction: Change in contract value due to commercialization success of the client’s product
- Contract Title: Contract Manufacturing Agreement for Pharmaceutical Products
- Counterparty: Merck Sharp & Dohme (Switzerland) GmbH
- Pre-correction Contract Amount: KRW 92,769,116,464 (3.09% of Recent Annual Revenue) / USD 70,579,060
- Post-correction Contract Amount: KRW 247,342,556,464 (8.24% of Recent Annual Revenue) / USD 188,179,060
- Increased Value: KRW 154,573,440,000 (USD 117,600,000 increase)
- Recent Annual Revenue: KRW 3,001,295,197,683 (Based on 2022 consolidated financial statements)
- Contract Execution Date & Initial Disclosure Date: March 12, 2024 (Applied Exchange Rate: USD/KRW 1,314.40)
- Contract Period: March 1, 2024 ~ December 31, 2032
- Other Remarks: Contract end date is subject to change based on mutual agreement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Revenue Recognition Following Contract Expansion Driven by Commercialization Success
This disclosure update reports a substantial increase of KRW 154.6B in the contract manufacturing agreement originally signed in March 2024, following the commercialization success of the client’s product. Because long-term supply terms and completion schedules remain subject to mutual agreement, tracking how this increased contract value is recognized in actual revenue over the contract period is essential. Verifying this progress helps investors understand the concrete financial impact of successful product commercialization on the company’s income statement over time. Relevant developments can be verified through subsequent Quarterly, Half-Yearly, and Annual Reports, as well as notes to financial statements.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
